Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

By The Northwire Desk — AI Analysis Mar 10, 2026 · 07:00 MSCL · 15.77 SATELLOS BIOSCIENCE INC.
MSCL · Price

Executive Summary

  • Satellos presented interim efficacy observations from its Phase 2 TRAILHEAD study showing continued hand‑grip strength gains and stable elbow/shoulder strength in adult DMD participants.
  • Proteomic analysis of the completed 28‑day CL‑101 Phase 1a/b trial revealed reductions in established DMD biomarkers (AK1, CA3, ENO3, MB, ANKRD2) within two weeks of SAT‑3247 dosing.
  • Preclinical mouse studies demonstrated significant muscle‑strength improvements in a model of facioscapulohumeral muscular dystrophy (FSHD), supporting broader therapeutic potential.

Key Details

  • TRAILHEAD Phase 2 (adult DMD):
  • Hand‑grip strength continued to increase versus CL‑101 baseline.
  • Elbow and shoulder strength remained stable through Day 56 after re‑enrollment.

  • Participants with higher baseline muscle mass showed greater strength improvements.

  • CL‑101 Phase 1a/b (28‑day DMD cohort):

  • Serum proteomic profiling of >11,000 proteins identified consistent biomarker reductions after two weeks of SAT‑3247.
  • Biomarkers decreased: AK1, CA3, ENO3, MB, ANKRD2.

  • Changes observed across all evaluated participants with comparable magnitude.

  • Regeneration Index (RI) Tool:

  • Novel RI based on established biomarkers was presented; now being applied in the ongoing BASECAMP pediatric study to assess muscle regeneration.

  • Preclinical FSHD Mouse Model:

  • Twelve‑week dosing of SAT‑3247 produced statistically significant enhancements in muscle strength versus control.

  • Findings suggest applicability of SAT‑3247 beyond DMD.

  • Conference Presentation:

  • Two oral presentations and three poster sessions delivered at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, Orlando, FL.

  • Future Plans:

  • Continued enrollment in TRAILHEAD and BASECAMP studies.
  • Additional clinical outcome assessments ongoing; full data to be posted on Satellos’ Events & Presentations page.

Notable Quotes

“Seeing continued improvements in handgrip strength and the addition of new muscle measurements by dynamometry is both positive and encouraging.” – Frank Gleeson, Co‑founder & CEO, Satellos Bioscience

“Participants with greater baseline muscle mass are demonstrating greater improvements in strength, further supporting our strategy of evaluating SAT‑3247 earlier in disease progression.” – Wildon Farwell, M.D., Chief Medical Officer, Satellos

Read the original news release →

More from SATELLOS BIOSCIENCE INC.

Jun 29, 2026 · 07:00

Fast Track designation adds another regulatory tailwind, but clinical data in H2 2026 remains the true catalyst.

Regulatory May 15, 2026 · 07:00

Satellos Secures Runway to 2027 as Phase 2 DMD Trials Advance, But Burn Rate Accelerates

Earnings Mar 27, 2026 · 07:00

Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

Earnings Feb 12, 2026 · 12:38

Satellos says first participant dosed in DMD study

Other Feb 12, 2026 · 07:00

Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

Production / Operations Feb 09, 2026 · 17:00

Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares

Financings